Clinical trial

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

NCT06099990

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2023-10-01

PhasePHASE1

Study timeline

Study start (estimated)2023-10-01Date precision: month

Registry last updated2023-10-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)unresolved

Interventions

dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tabletsDRUG

placebo; abiraterone acetate tablets; prednisone tabletsDRUG

Sponsors & collaborators

Jiangsu HengRui Medicine Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06099990 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.